Stock Track | Cellebrite Soars 18.47% on Strong Q3 Results, Federal Business Growth, and Positive Outlook

Stock Track
11/13

Cellebrite (CLBT), a leader in digital investigative solutions, saw its stock surge 18.47% in Wednesday's trading session following the release of its impressive third-quarter 2025 financial results and optimistic future outlook.

The company reported Q3 revenue of $126.03 million, surpassing analyst expectations of $122.01 million and marking an 18% year-over-year increase. Subscription revenue, a key growth driver, jumped 21% to $112.7 million. Cellebrite's Annual Recurring Revenue (ARR) reached $439.8 million, up 19% from the previous year, demonstrating strong customer retention and expansion.

CEO Thomas E. Hogan highlighted the company's "balanced and solid performance," noting significant expansion within the U.S. Federal business segment. This growth, coupled with strong demand in U.S. state and local markets and Latin America, contributed to the overall positive results. The company's Autumn 2025 Release, which introduced new capabilities and integrations to its Digital Investigation Platform, further solidified its market position.

Looking ahead, Cellebrite provided an optimistic outlook for the remainder of 2025 and beyond. The company expects full-year 2025 revenue between $470 million and $475 million, representing a 17% to 18% annual growth. Additionally, Cellebrite anticipates Q4 2025 adjusted EBITDA in the range of $35 million to $38 million, signaling continued strong performance. This positive guidance, combined with the strong Q3 results and expansion in key business segments, likely fueled investor confidence and contributed to the significant stock price increase.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10